PIN1 and triple-negative breast carcinoma: Ablating Pin1 enzymatic activity with Sulfopin, a selective Pin1 inhibitor, was successful at blocking MYC-driven tumors like pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer, in vitro and in vivo (Dubiella et al., 2021).